[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100391818":3},{"organization":4,"armGroups":7,"interventions":118,"overallOfficials":201,"centralContacts":205,"locations":211,"responsibleParty":410,"collaborators":412,"id":433,"slug":434,"hasResults":435,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":435,"sex":440,"minAge":441,"maxAge":12,"enrollmentInfo":442,"targetDuration":12,"studyType":445,"phases":446,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":214,"whyStopped":12,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":470},{"fullName":5,"class":6},"University of Oxford","OTHER",[8,13,19,23,27,31,36,41,46,50,55,59,64,69,74,79,84,89,94,99,104,109,114],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Care","NO_INTERVENTION","Patient receives usual hospital care",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Corticosteroids","ACTIVE_COMPARATOR","First (main) randomisation part A (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[18],"Drug: Corticosteroid",{"label":20,"type":15,"description":16,"interventionNames":21},"Hydroxychloroquine",[22],"Drug: Hydroxychloroquine",{"label":24,"type":15,"description":16,"interventionNames":25},"Lopinavir-Ritonavir",[26],"Drug: Lopinavir-Ritonavir",{"label":28,"type":15,"description":16,"interventionNames":29},"Azithromycin",[30],"Drug: Azithromycin",{"label":32,"type":15,"description":33,"interventionNames":34},"Convalescent plasma","First (main) randomisation part B (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[35],"Biological: Convalescent plasma",{"label":37,"type":15,"description":38,"interventionNames":39},"Tocilizumab","Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment.\n\n(Children with COVID-19 pneumonia are not eligible for this comparison).\n\n\\[This arm is now closed to recruitment\\]",[40],"Drug: Tocilizumab",{"label":42,"type":15,"description":43,"interventionNames":44},"Intravenous Immunoglobulin","First (main) randomisation part A (children only)\n\n\\[This arm is now closed to recruitment\\]",[45],"Biological: Immunoglobulin",{"label":47,"type":15,"description":33,"interventionNames":48},"Synthetic neutralising antibodies",[49],"Drug: Synthetic neutralising antibodies",{"label":51,"type":15,"description":52,"interventionNames":53},"Aspirin","First (main) randomisation part C (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[54],"Drug: Aspirin",{"label":56,"type":15,"description":16,"interventionNames":57},"Colchicine",[58],"Drug: Colchicine",{"label":60,"type":15,"description":61,"interventionNames":62},"Baricitinib","First (main) randomisation part D (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[63],"Drug: Baricitinib",{"label":65,"type":15,"description":66,"interventionNames":67},"Anakinra","Randomisation for children only with PIMS-TS\n\n(Children with COVID-19 pneumonia are not eligible for this comparison).\n\n\\[This arm is now closed to recruitment\\]",[68],"Drug: Anakinra",{"label":70,"type":15,"description":71,"interventionNames":72},"Dimethyl fumarate","First (main) randomisation part A (COVID-19) (UK adults only; early phase assessment)\n\n\\[This arm is now closed to recruitment\\]",[73],"Drug: Dimethyl fumarate",{"label":75,"type":15,"description":76,"interventionNames":77},"High Dose Corticosteroids","First (main) randomisation part E (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[78],"Drug: High Dose Corticosteroid",{"label":80,"type":15,"description":81,"interventionNames":82},"Empagliflozin","First (main) randomisation part F (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[83],"Drug: Empagliflozin",{"label":85,"type":15,"description":86,"interventionNames":87},"Sotrovimab","First (main) randomisation part J (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[88],"Drug: Sotrovimab",{"label":90,"type":15,"description":91,"interventionNames":92},"Molnupiravir","First (main) randomisation part K (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[93],"Drug: Molnupiravir",{"label":95,"type":15,"description":96,"interventionNames":97},"Paxlovid","First (main) randomisation part L (COVID-19)\n\n\\[This arm is now closed to recruitment\\]",[98],"Drug: Paxlovid",{"label":100,"type":15,"description":101,"interventionNames":102},"Baloxavir marboxil","Randomisation part G (influenza)",[103],"Drug: Baloxavir Marboxil",{"label":105,"type":15,"description":106,"interventionNames":107},"Oseltamivir","Randomisation part H (influenza)",[108],"Drug: Oseltamivir",{"label":110,"type":15,"description":111,"interventionNames":112},"Corticosteroids (dexamethasone) (influenza arm)","Randomisation part I (influenza)",[113],"Drug: Corticosteroids (dexamethasone)",{"label":115,"type":15,"description":116,"interventionNames":117},"Corticosteroids (dexamethasone) (community-acquired pneumonia arm)","Randomisation part M (community-acquired pneumonia)",[113],[119,123,127,130,133,137,140,144,150,153,156,159,162,165,169,172,175,178,183,189,194,198],{"type":120,"name":24,"description":121,"armGroupLabels":122,"otherNames":12},"DRUG","Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.",[24],{"type":120,"name":124,"description":125,"armGroupLabels":126,"otherNames":12},"Corticosteroid","Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \\>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)",[14],{"type":120,"name":20,"description":128,"armGroupLabels":129,"otherNames":12},"Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).",[20],{"type":120,"name":28,"description":131,"armGroupLabels":132,"otherNames":12},"Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.",[28],{"type":134,"name":32,"description":135,"armGroupLabels":136,"otherNames":12},"BIOLOGICAL","Single unit of ABO compatible convalescent plasma (275mls +\u002F- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).",[32],{"type":120,"name":37,"description":138,"armGroupLabels":139,"otherNames":12},"Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)",[37],{"type":134,"name":141,"description":142,"armGroupLabels":143,"otherNames":12},"Immunoglobulin","Intravenous immunoglobulin (IVIg) for children \\>44 weeks gestational age and \\\u003C18 years with PIMS-TS only (see Protocol for dosage)",[42],{"type":120,"name":47,"description":145,"armGroupLabels":146,"otherNames":147},"Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +\u002F- 15 minutes as soon as possible after randomisation",[47],[148,149],"REGEN-COV","casirivimab and imdevimab",{"type":120,"name":51,"description":151,"armGroupLabels":152,"otherNames":12},"150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.",[51],{"type":120,"name":56,"description":154,"armGroupLabels":155,"otherNames":12},"1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only",[56],{"type":120,"name":60,"description":157,"armGroupLabels":158,"otherNames":12},"UK \\[age ≥2 years with COVID pneumonia\\] and India \\[age ≥18 years with COVID-19 pneumonia\\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.",[60],{"type":120,"name":65,"description":160,"armGroupLabels":161,"otherNames":12},"For children ≥1 \\\u003C18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \\\u003C10 kg in weight.",[65],{"type":120,"name":70,"description":163,"armGroupLabels":164,"otherNames":12},"Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).",[70],{"type":120,"name":166,"description":167,"armGroupLabels":168,"otherNames":12},"High Dose Corticosteroid","Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.",[75],{"type":120,"name":80,"description":170,"armGroupLabels":171,"otherNames":12},"Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).",[80],{"type":120,"name":85,"description":173,"armGroupLabels":174,"otherNames":12},"UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.",[85],{"type":120,"name":90,"description":176,"armGroupLabels":177,"otherNames":12},"Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.",[90],{"type":120,"name":95,"description":179,"armGroupLabels":180,"otherNames":181},"UK patients ≥18 years old. 300\u002F100 mg twice daily for 5 days by mouth.",[95],[182],"nirmatrelvir\u002Fritonavir",{"type":120,"name":184,"description":185,"armGroupLabels":186,"otherNames":187},"Baloxavir Marboxil","Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.\n\n40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4.",[100],[188],"Xofluza",{"type":120,"name":105,"description":190,"armGroupLabels":191,"otherNames":192},"Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.\n\n75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)",[105],[193],"Tamiflu",{"type":120,"name":195,"description":196,"armGroupLabels":197,"otherNames":12},"Corticosteroids (dexamethasone)","Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \\\u003C92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)",[110],{"type":120,"name":195,"description":199,"armGroupLabels":200,"otherNames":12},"Patients ≥18 years old with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)",[115],[202],{"name":203,"affiliation":5,"role":204},"Peter W Horby","PRINCIPAL_INVESTIGATOR",[206],{"name":207,"role":208,"phone":209,"phoneExt":12,"email":210},"Leon Peto","CONTACT","+44 (0)1865 743743","recoverytrial@ndph.ox.ac.uk",[212,227,239,251,264,276,286,298,308,321,333,345,358,370,382,396],{"facility":213,"status":214,"city":215,"state":12,"zip":12,"country":216,"countryCode":217,"cosmosGeoPoint":218,"geoPoint":223,"contacts":224},"Belgian sites are managed by the European Clinical Research Alliance on Infectious Diseases","RECRUITING","Brussels","Belgium","BE",{"type":219,"coordinates":220},"Point",[221,222],4.34878,50.85045,{"lat":222,"lon":221},[225],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},"info@ecraid.eu",{"facility":228,"status":214,"city":229,"state":12,"zip":12,"country":230,"countryCode":231,"cosmosGeoPoint":232,"geoPoint":236,"contacts":237},"Estonian sites are managed by the European Clinical Research Alliance on Infectious Diseases","Tallinn","Estonia","EE",{"type":219,"coordinates":233},[234,235],24.75353,59.43696,{"lat":235,"lon":234},[238],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},{"facility":240,"status":214,"city":241,"state":12,"zip":12,"country":242,"countryCode":243,"cosmosGeoPoint":244,"geoPoint":248,"contacts":249},"French sites are managed by the European Clinical Research Alliance on Infectious Diseases","Paris","France","FR",{"type":219,"coordinates":245},[246,247],2.3488,48.85341,{"lat":247,"lon":246},[250],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},{"facility":252,"status":214,"city":253,"state":12,"zip":12,"country":254,"countryCode":255,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"Kumasi Center for Collaborative Research in Tropical Medicine KNUST","Kumasi","Ghana","GH",{"type":219,"coordinates":257},[258,259],-1.62443,6.68848,{"lat":259,"lon":258},[262],{"name":12,"role":208,"phone":263,"phoneExt":12,"email":12},"+233 278 364 389",{"facility":265,"status":266,"city":267,"state":12,"zip":268,"country":269,"countryCode":270,"cosmosGeoPoint":271,"geoPoint":275,"contacts":12},"Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases","COMPLETED","New Delhi","ICMR-110029","India","IN",{"type":219,"coordinates":272},[273,274],77.2148,28.62137,{"lat":274,"lon":273},{"facility":277,"status":214,"city":278,"state":12,"zip":12,"country":279,"countryCode":280,"cosmosGeoPoint":281,"geoPoint":285,"contacts":12},"Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology","Jakarta","Indonesia","ID",{"type":219,"coordinates":282},[283,284],106.84513,-6.21462,{"lat":284,"lon":283},{"facility":287,"status":214,"city":288,"state":12,"zip":12,"country":289,"countryCode":290,"cosmosGeoPoint":291,"geoPoint":295,"contacts":296},"Italian sites are managed by the European Clinical Research Alliance on Infectious Diseases","Roma","Italy","IT",{"type":219,"coordinates":292},[293,294],11.10642,44.99364,{"lat":294,"lon":293},[297],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},{"facility":299,"status":214,"city":300,"state":12,"zip":12,"country":301,"countryCode":302,"cosmosGeoPoint":303,"geoPoint":307,"contacts":12},"Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences","Kathmandu","Nepal","NP",{"type":219,"coordinates":304},[305,306],85.3206,27.70169,{"lat":306,"lon":305},{"facility":309,"status":214,"city":310,"state":12,"zip":311,"country":312,"countryCode":313,"cosmosGeoPoint":314,"geoPoint":318,"contacts":319},"Dutch sites are managed by the European Clinical Research Alliance on Infectious Diseases","Utrecht","3584 BA","Netherlands","NL",{"type":219,"coordinates":315},[316,317],5.12222,52.09083,{"lat":317,"lon":316},[320],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},{"facility":322,"status":214,"city":323,"state":12,"zip":12,"country":324,"countryCode":325,"cosmosGeoPoint":326,"geoPoint":330,"contacts":331},"Portuguese sites are managed by the European Clinical Research Alliance on Infectious Diseases","Lisbon","Portugal","PT",{"type":219,"coordinates":327},[328,329],-9.1498,38.72509,{"lat":329,"lon":328},[332],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},{"facility":334,"status":214,"city":335,"state":12,"zip":12,"country":336,"countryCode":337,"cosmosGeoPoint":338,"geoPoint":342,"contacts":343},"Romanian sites are managed by the European Clinical Research Alliance on Infectious Diseases","Bucharest","Romania","RO",{"type":219,"coordinates":339},[340,341],26.10626,44.43225,{"lat":341,"lon":340},[344],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},{"facility":346,"status":214,"city":347,"state":12,"zip":12,"country":348,"countryCode":349,"cosmosGeoPoint":350,"geoPoint":354,"contacts":355},"Wits Health Consortium","Johannesburg","South Africa","ZA",{"type":219,"coordinates":351},[352,353],28.04363,-26.20227,{"lat":353,"lon":352},[356],{"name":12,"role":208,"phone":357,"phoneExt":12,"email":12},"+27 11 274 9200",{"facility":359,"status":214,"city":360,"state":12,"zip":12,"country":361,"countryCode":362,"cosmosGeoPoint":363,"geoPoint":367,"contacts":368},"Spanish sites are managed by the European Clinical Research Alliance on Infectious Diseases","Barcelona","Spain","ES",{"type":219,"coordinates":364},[365,366],2.15899,41.38879,{"lat":366,"lon":365},[369],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},{"facility":371,"status":214,"city":372,"state":12,"zip":12,"country":373,"countryCode":374,"cosmosGeoPoint":375,"geoPoint":379,"contacts":380},"Swedish sites are managed by the European Clinical Research Alliance on Infectious Diseases","Stockholm","Sweden","SE",{"type":219,"coordinates":376},[377,378],18.06871,59.32938,{"lat":378,"lon":377},[381],{"name":12,"role":208,"phone":12,"phoneExt":12,"email":226},{"facility":383,"status":214,"city":384,"state":12,"zip":385,"country":386,"countryCode":387,"cosmosGeoPoint":388,"geoPoint":392,"contacts":393},"Nuffield Department of Population Health, University of Oxford","Oxford","OX3 7LF","United Kingdom","UK",{"type":219,"coordinates":389},[390,391],-1.25596,51.75222,{"lat":391,"lon":390},[394,395],{"name":203,"role":208,"phone":12,"phoneExt":12,"email":210},{"name":203,"role":204,"phone":12,"phoneExt":12,"email":12},{"facility":397,"status":214,"city":398,"state":12,"zip":12,"country":399,"countryCode":400,"cosmosGeoPoint":401,"geoPoint":405,"contacts":406},"Oxford University Clinical Research Unit, Centre for Tropical Medicine","Ho Chi Minh City","Vietnam","VN",{"type":219,"coordinates":402},[403,404],106.62965,10.82302,{"lat":404,"lon":403},[407],{"name":12,"role":208,"phone":408,"phoneExt":12,"email":409},"+84 8 39241983","recoverytrial@oucru.org",{"type":411,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[413,415,418,420,422,424,427,429,431],{"name":414,"class":6},"UK Research and Innovation",{"name":416,"class":417},"National Institute for Health Research, United Kingdom","OTHER_GOV",{"name":419,"class":6},"Wellcome Trust",{"name":421,"class":6},"Bill and Melinda Gates Foundation",{"name":423,"class":417},"Department for International Development, United Kingdom",{"name":425,"class":426},"Health Data Research UK","UNKNOWN",{"name":428,"class":426},"Medical Research Council Population Health Research Unit",{"name":430,"class":426},"NIHR Health Protection Research Unit in Emerging and Zoonotic Infections",{"name":432,"class":426},"Flu Lab","100391818","phase-3-randomised-evaluation-of-covid-19-therapy-100391818",false,"NCT04381936","Randomised Evaluation of COVID-19 Therapy","RECOVERY","Eligibility Criteria (as per Protocol v28.0):\n\nPatients are eligible for the study if all of the following are true:\n\n(i) Hospitalised\n\n(ii) Pneumonia syndrome\n\nIn general, pneumonia should be suspected when a patient presents with:\n\n1. typical symptoms of a new respiratory tract infection (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and\n2. objective evidence of acute lung disease (e.g. consolidation or ground-glass shadowing on X-ray or CT, hypoxia, or compatible clinical examination); and\n3. alternative causes have been considered unlikely or excluded (e.g. heart failure).\n\nHowever, the diagnosis remains a clinical one based on the opinion of the managing doctor (the above criteria are just a guide).\n\n(iii) One of the following diagnoses:\n\n1. Confirmed influenza A or B infection (including patients with SARS-CoV-2 co-infection)\n2. Community-acquired pneumonia (CAP) with planned antibiotic treatment (excluding patients with suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia)\n\n(iv) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he\u002Fshe were to participate in the trial\n\nPatients with suspected or confirmed active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia (also known as PCP or PJP) are excluded from the CAP comparison, as these infections are caused by specific organisms with distinct pathologies, and so are not usually categorised as CAP. Eligibility for the CAP comparison also requires planned antibiotic treatment, so patients being treated solely for fungal or viral pneumonia are not eligible.\n\nPatients with SARS-CoV-2 and influenza co-infection are eligible, but would be excluded from certain comparisons if the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms (see Protocol Appendix 2, Appendix 3 for children, and Appendix 4 for pregnant and breastfeeding women), or that the patient should definitely be receiving one of the active drug treatment arms then that arm will not be available for randomisation for that patient. For patients who lack capacity, an advanced directive or behaviour that clearly indicates that they would not wish to participate in the trial would be considered sufficient reason to exclude them from the trial.\n\nPatients who have been previously recruited into RECOVERY are eligible to be recruited again as long as their previous randomisation was \\>6 months ago. Patients will not be recruited into the same randomised comparison (e.g. sotrovimab vs. usual care) on more than one occasion, regardless of how far apart they occur.\n\nIn some locations, children (aged \\\u003C18 years) will not be recruited, to comply with local and national regulatory approvals (see Appendix 6).\n\nNote: the eligibility criteria has changed from COVID-19 to pneumonia (Influenza \\& CAP). For detailed information about previous eligibility criteria please see the previous Protocol's on the study website: https:\u002F\u002Fwww.recoverytrial.net\u002Fuk\u002Ffor-site-staff\u002Fsite-set-up-1\u002Fregulatory-documents","ALL","0 Years",{"count":443,"type":444},70000,"ESTIMATED","INTERVENTIONAL",[447],"PHASE3","RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia.\n\nThe treatments being investigated are:\n\nCOVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only)\n\nInfluenza: Baloxavir marboxil, Oseltamivir, Corticosteroids (dexamethasone)\n\nCommunity-acquired pneumonia: Corticosteroids (dexamethasone)",[450],"Pneumonia",[452,453,454,455,456,457,458,459,460],"COVID-19","SARS-CoV-2","SARS coronavirus 2","SARS","Viral pneumonia syndrome","Community-acquired pneumonia","Bacterial pneumonia syndrome","Influenza A","Influenza B","2026-04-15",{"date":463,"type":464},"2026-04-21","ACTUAL",{"date":466,"type":464},"2020-03-19",{"date":468,"type":444},"2038-09-30",{"name":5,"class":6},16]